Literature DB >> 33653185

Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration.

Deepa Denesh1, Jenelyn Carbonell1, John S Kane1, David Gracie1,2, Christian P Selinger1,2.   

Abstract

Objectives: With increasing treatment choices for inflammatory bowel disease (IBD), patients' preferences should be considered to limit non-adherence. We explored patients' preferences for route, form and frequency of medication administration, and factors influencing these choices.
Methods: Patients rated acceptability of different forms of medication on 10-point Likert scales and preferences for highest acceptable frequency.
Results: Of 298 patients significantly more found tablets (91%) to be highly acceptable compared to granules (64%), infusions (33%) and subcutaneous injections (34%; p < 0.0001). The acceptable frequency for tablets was considered as daily by 63.5% and several times daily by 32.3%. Participants preferred nurse delivered over self-administered injections (median score 8 vs 5, p < 0.0001) and hospital-based infusions over infusions at home (median score 7 vs 5, p = 0.001). Patients with previous or current anti-TNF exposure were more accepting of self-administered injections (50.5% vs 23.3% anti-TNF naive; p < 0.001), more accepting of home based infusions (43.7% vs 28.0%; p = 0.001) and more accepting of hospital-based infusions (57.2% vs 37.8%; p = 0.02).
Conclusion: Most patients with IBD prefer tablets. Those patients who already experienced biological agents, had a high level of acceptance for subcutaneous and intravenous forms of medication.

Entities:  

Keywords:  Crohn’s disease; Ulcerative colitis; adherence; inflammatory bowel disease; medication

Mesh:

Substances:

Year:  2021        PMID: 33653185     DOI: 10.1080/17474124.2021.1898944

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  6 in total

1.  The ulcerative colitis narrative Greece survey: patients' and physicians' perspective on quality of life and disease management.

Authors:  Nikos Viazis; Anastasia Stefanidou; Gerasimos J Mantzaris
Journal:  Ann Gastroenterol       Date:  2022-03-25

2.  Interactions Between Ephedra sinica and Prunus armeniaca: From Stereoselectivity to Deamination as a Metabolic Detoxification Mechanism of Amygdalin.

Authors:  Yan Qin; Shanshan Wang; Qiuyu Wen; Quan Xia; Sheng Wang; Guanjun Chen; Jiayin Sun; Chenlin Shen; Shuai Song
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

3.  Development and Validation of a Digital Image Processing-Based Pill Detection Tool for an Oral Medication Self-Monitoring System.

Authors:  Jannis Holtkötter; Rita Amaral; Rute Almeida; Cristina Jácome; Ricardo Cardoso; Ana Pereira; Mariana Pereira; Ki H Chon; João Almeida Fonseca
Journal:  Sensors (Basel)       Date:  2022-04-12       Impact factor: 3.576

Review 4.  Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.

Authors:  Jan Marsal; Manuel Barreiro-de Acosta; Irina Blumenstein; Maria Cappello; Thomas Bazin; Shaji Sebastian
Journal:  Front Med (Lausanne)       Date:  2022-06-15

5.  Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease.

Authors:  E H J Savelkoul; M H J Maas; A R Bourgonje; F Crouwel; V B C Biemans; N den Broeder; M G V M Russel; T E H Römkens; N K de Boer; G Dijkstra; F Hoentjen
Journal:  J Crohns Colitis       Date:  2022-09-08       Impact factor: 10.020

6.  Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations.

Authors:  Gemma Burdge; Alice Hardman; Isabel Carbery; Giacomo Broglio; Dan Greer; Christian P Selinger
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.